Chengdu Lisite Pharmaceutical

Chengdu Lisite Pharmaceutical is a Chinese pharmaceutical company specializing in the research, development, and manufacturing of chemical drugs, with a particular focus on hematology and cardiovascular health. The company is best known for its flagship product, Iron Proteinsuccinylate Oral Solution (marketed as Feiteng), which holds a significant market share in the treatment of iron deficiency anemia in China. Beyond hematology, Lisite produces a range of treatments for hypertension and gastrointestinal disorders. In 2019, the company was acquired by Haisco Pharmaceutical Group, a move that integrated Lisite's specialized product portfolio into Haisco's broader commercial network. The company operates modern, GMP-certified manufacturing facilities in the Chengdu Hi-Tech Industrial Development Zone.